# This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam

> **NCT03325712** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 705564
- **DRUG:** Placebo
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT03325712
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-17
- **Primary completion:** 2018-11-26
- **Final completion:** 2018-11-26
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325712, "This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03325712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*